relapsed or refractory multiple myeloma

Sanofi wins appeal in spat with NICE over Sarclisa
Pharmaphorum
Wed, 11/13/24 - 10:53 am
Sanofi
NHS
NICE
relapsed or refractory multiple myeloma
Sarclisa
Janssen granted additional European Commission approval for bispecific antibody
Biopharma Reporter
Tue, 08/22/23 - 09:54 am
Janssen
JNJ
bispecific antibodies
Europe
relapsed or refractory multiple myeloma
J&J bags first FDA approval for a GPRC5D drug
Pharmaphorum
Thu, 08/10/23 - 09:52 am
JNJ
FDA
GPRC5D
Talvey
relapsed or refractory multiple myeloma
FDA places clinical hold on Arcellx’s multiple myeloma therapy trial
Clinical Trials Arena
Tue, 06/20/23 - 09:57 am
Arcellx
CAR-T
CART-ddBCMA
relapsed or refractory multiple myeloma
FDA
clinical trials
ALX and Sanofi partner to start Phase l/ll trial of RRMM combo therapy
Clinical Trials Arena
Wed, 04/26/23 - 10:26 am
ALX Oncology
Sanofi
clinical trials
evorpacept
Sarclisa
relapsed or refractory multiple myeloma
REGN5459 Delivers Dose-Dependent Responses in Relapsed/Refractory Myeloma
Onc Live
Tue, 04/18/23 - 09:49 am
Regeneron
AACR
REGN5459
relapsed or refractory multiple myeloma
Pfizer’s Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma
Drugs.com
Fri, 11/4/22 - 11:03 am
Pfizer
elranatamab
FDA
breakthrough therapy
relapsed or refractory multiple myeloma
Oncopeptides Sees Redemption with Positive Multiple Myeloma Data after ODAC Vote
BioSpace
Wed, 10/26/22 - 06:40 pm
Oncopeptides
clinical trials
Pepaxto
relapsed or refractory multiple myeloma
Janssen secures FDA breakthrough designation for myeloma therapy
Pharmaceutical Business Review
Thu, 06/30/22 - 10:54 am
JNJ
Janssen
breakthrough therapy
FDA
talquetamab
Multiple Myeloma
relapsed or refractory multiple myeloma
ASCO22: J&J, Pfizer trade BCMA bispecific data in myeloma
Pharmaforum
Mon, 06/6/22 - 09:52 am
JNJ
Pfizer
ASCO 2022
bispecific antibodies
relapsed or refractory multiple myeloma
GSK nabs speedy review for one of its top prospects
Fierce Biotech
Tue, 01/21/20 - 11:46 am
GSK
FDA
priority review
BCMA
belantamab mafodotin
relapsed or refractory multiple myeloma
Bristol-Myers, AbbVie's multiple myeloma drug wins second EU nod as part of triple regimen
Endpoints
Wed, 08/28/19 - 12:38 pm
Bristol-Myers Squibb
AbbVie
Empliciti
Celgene
Europe
relapsed or refractory multiple myeloma
FDA accepts BLA filing for Sanofi's rival to J&J's Darzalex
Fierce Biotech
Wed, 07/10/19 - 10:30 am
Sanofi
FDA
Darzalex
relapsed or refractory multiple myeloma
isatuximab
Sanofi's isatuximab meets survival endpoint for third-line multiple myeloma
BioCentury
Tue, 02/5/19 - 10:09 am
Sanofi
FDA
EMA
isatuximab
relapsed or refractory multiple myeloma
Multiple Myeloma